Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

Westover KD, Loo BW Jr, Gerber DE, Iyengar P, Choy H, Diehn M, Hughes R, Schiller J, Dowell J, Wardak Z, Sher D, Christie A, Xie XJ, Corona I, Sharma A, Wadsworth ME, Timmerman R.

Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81. doi: 10.1016/j.ijrobp.2015.05.004. Epub 2015 May 9.

PMID:
26279026
2.

Development of small molecules targeting the pseudokinase Her3.

Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS.

Bioorg Med Chem Lett. 2015 Aug 15;25(16):3382-9. doi: 10.1016/j.bmcl.2015.04.103. Epub 2015 May 11.

PMID:
26094118
3.

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD.

Mol Cancer Res. 2015 Sep;13(9):1325-35. doi: 10.1158/1541-7786.MCR-15-0203. Epub 2015 Jun 2.

PMID:
26037647
4.

SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.

Westover KD, Iyengar P, Sharma AN, Timmerman R.

Lung Cancer. 2015 Aug;89(2):87-93. doi: 10.1016/j.lungcan.2015.04.009. Epub 2015 May 8. Review.

PMID:
26028304
5.

Pharmacological targeting of the pseudokinase Her3.

Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS.

Nat Chem Biol. 2014 Dec;10(12):1006-12. doi: 10.1038/nchembio.1658. Epub 2014 Oct 19.

6.

Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.

Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, Timmerman R.

J Thorac Oncol. 2015 Feb;10(2):280-5. doi: 10.1097/JTO.0000000000000399.

PMID:
25299234
7.

Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).

Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS.

J Med Chem. 2015 Jan 8;58(1):183-96. doi: 10.1021/jm500480k. Epub 2014 Jul 30.

8.

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.

Hunter JC, Gurbani D, Ficarro SB, Carrasco MA, Lim SM, Choi HG, Xie T, Marto JA, Chen Z, Gray NS, Westover KD.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8895-900. doi: 10.1073/pnas.1404639111. Epub 2014 Jun 2.

9.

Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer.

Laine AM, Westover KD, Choy H.

Semin Oncol. 2014 Feb;41(1):57-68. doi: 10.1053/j.seminoncol.2013.12.012. Epub 2013 Dec 12. Review.

PMID:
24565581
10.

Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.

Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, Meyerson M, Marto JA, Engen JR, Gray NS.

Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. doi: 10.1002/anie.201307387. Epub 2013 Nov 20.

11.

Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.

Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabef A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS.

Cancer Res. 2013 Apr 15;73(8):2574-86. doi: 10.1158/0008-5472.CAN-12-1702. Epub 2013 Feb 22.

12.

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.

Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S.

Cell. 2012 Aug 31;150(5):987-1001. doi: 10.1016/j.cell.2012.06.047.

13.

Proton SBRT for medically inoperable stage I NSCLC.

Westover KD, Seco J, Adams JA, Lanuti M, Choi NC, Engelsman M, Willers H.

J Thorac Oncol. 2012 Jun;7(6):1021-5. doi: 10.1097/JTO.0b013e31824de0bf.

14.

Should a sentinel node biopsy be performed in patients with high-risk breast cancer?

Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS.

Int J Breast Cancer. 2011;2011:973245. doi: 10.4061/2011/973245. Epub 2011 Aug 10.

15.

Significance testing as perverse probabilistic reasoning.

Westover MB, Westover KD, Bianchi MT.

BMC Med. 2011 Feb 28;9:20. doi: 10.1186/1741-7015-9-20.

16.

Comprehensive and efficient HBB mutation analysis for detection of beta-hemoglobinopathies in a pan-ethnic population.

Chan OT, Westover KD, Dietz L, Zehnder JL, Schrijver I.

Am J Clin Pathol. 2010 May;133(5):700-7. doi: 10.1309/AJCP7HQ2KWGHECIO.

17.

Structural basis of transcription: backtracked RNA polymerase II at 3.4 angstrom resolution.

Wang D, Bushnell DA, Huang X, Westover KD, Levitt M, Kornberg RD.

Science. 2009 May 29;324(5931):1203-6. doi: 10.1126/science.1168729.

18.

Structural basis of transcription: role of the trigger loop in substrate specificity and catalysis.

Wang D, Bushnell DA, Westover KD, Kaplan CD, Kornberg RD.

Cell. 2006 Dec 1;127(5):941-54.

19.

Structural basis of eukaryotic gene transcription.

Boeger H, Bushnell DA, Davis R, Griesenbeck J, Lorch Y, Strattan JS, Westover KD, Kornberg RD.

FEBS Lett. 2005 Feb 7;579(4):899-903. Review.

20.

Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center.

Batada NN, Westover KD, Bushnell DA, Levitt M, Kornberg RD.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17361-4. Epub 2004 Dec 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk